Posaconazole treatment of extensive skin and nail dermatophytosis due to autosomal recessive deficiency of CARD9

JAMA Dermatology

Volumn 151, Issue 2, 2015, Pages 192-194

  Jachiet, Marie ^a   Lanternier, Fanny ^b,c   Rybojad, Michel ^a   Bagot, Martine ^a   Ibrahim, Lina ^a   Casanova, Jean Laurent ^b   Puel, Anne ^b   Bouaziz, Jean David ^a  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^b IMAGINE INSTITUTE   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CICLOPIROXOLAMINE; ITRACONAZOLE; KETOCONAZOLE; POSACONAZOLE; TERBINAFINE; CARD9 PROTEIN, HUMAN; CASPASE RECRUITMENT DOMAIN SIGNALING PROTEIN; TRIAZOLE DERIVATIVE;

ACANTHOSIS; ARTICLE; AUTOSOMAL RECESSIVE DISORDER; CASE REPORT; CASPASE RECRUITMENT DOMAIN 9 GENE; CLINICAL EXAMINATION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG INDICATION; EGYPTIAN; FINGERNAIL ONYCHOMYCOSIS; FOLLOW UP; GENE; GENE MUTATION; GENETIC VARIABILITY; HUMAN; HUMAN TISSUE; HYPEREOSINOPHILIA; HYPERKERATOSIS; MALE; NAIL DERMATOPHYTOSIS; NAIL INFECTION; ONYCHOLYSIS; PHENOTYPE; PRURITUS; REMISSION; SKIN BIOPSY; SKIN DERMATOPHYTOSIS; SKIN INFECTION; STOP CODON; TRICHOPHYTON RUBRUM INFECTION; ADULT; BIOPSY; DEFICIENCY; GENETICS; MUTATION; NAIL; NUCLEOTIDE SEQUENCE; PATHOLOGY; RECESSIVE GENE; SKIN; TINEA;

ADULT; BIOPSY; CARD SIGNALING ADAPTOR PROTEINS; DNA MUTATIONAL ANALYSIS; FOLLOW-UP STUDIES; GENES, RECESSIVE; HUMANS; MALE; MUTATION; NAILS; PHENOTYPE; SKIN; TINEA; TRIAZOLES;

EID: 84922854771     PISSN: 21686068     EISSN: 21686084     Source Type: Journal    
DOI: 10.1001/jamadermatol.2014.2154     Document Type: Article

References (15)

1. Seebacher C, Bouchara J-P, Mignon B. Updates on the epidemiology of dermatophyte infections. Mycopathologia. 2008;166(5-6):335-352.
2. Degreef H. Clinical forms of dermatophytosis (ringworm infection). Mycopathologia. 2008;166 (5-6):257-265.
3. De Pauw B, Walsh TJ, Donnelly JP, et al; European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group; National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis. 2008;46(12):1813-1821.
4. Cheikhrouhou F, Makni F, Masmoudi A, Sellami A, Turki H, Ayadi A. A fatal case of dermatomycoses with retropharyngeal abscess [in French]. Ann Dermatol Venereol. 2010;137(3):208-211.
5. Liautaud B, Marill FG. Dermatophytic disease: recent Algerian observations [in French]. Bull Soc Pathol Exot Filiales. 1984;77(5):637-648.
6. Lanternier F, Pathan S, Vincent QB, et al. Deep dermatophytosis and inherited CARD9 deficiency. N Engl J Med. 2013;369(18):1704-1714.
7. Hsu Y-MS, Zhang Y, You Y, et al. The adaptor protein CARD9 is required for innate immune responses to intracellular pathogens. Nat Immunol. 2007;8(2):198-205.
8. Gavino C, Cotter A, Lichtenstein D, et al. CARD9 deficiency and spontaneous central nervous system candidiasis: complete clinical remission with GM-CSF therapy [published online May 9, 2014]. Clin Infect Dis. 2014. doi:10.1093/cid/ciu215.
9. H17 cell deficiencies. J Allergy Clin Immunol. 2014; 133(3):905.e3-908.e3. doi:10.1016/j.jaci.2013.09.033.
10. Glocker EO, Hennigs A, Nabavi M, et al. A homozygous CARD9 mutationin a family with susceptibility to fungal infections. N Engl J Med. 2009;361(18):1727-1735.
11. Drewniak A, Gazendam RP, Tool AT, et al. Invasive fungal infection and impaired neutrophil killing in human CARD9 deficiency. Blood. 2013;121 (13):2385-2392.
12. Barchiesi F, Arzeni D, Camiletti V, et al. In vitro activity of posaconazole against clinical isolates of dermatophytes. J Clin Microbiol. 2001;39(11): 4208-4209.
13. Krishna G, Ma L, Martinho M, Prasad P, Wahl J, Tavakkol A. Determination of posaconazole levels in toenails of adults with onychomycosis following oral treatment with four regimens of posaconazole for 12 or 24 weeks. Antimicrob Agents Chemother. 2011;55(9):4424-4426.
14. Krishna G, Beresford E, Ma L, et al. Skin concentrations and pharmacokinetics of posaconazole after oral administration. Antimicrob Agents Chemother. 2010;54(5):1807-1810.
15. Gupta AK, Kohli Y, Batra R. In vitro activities of posaconazole, ravuconazole, terbinafine, itraconazole and fluconazole against dermatophyte, yeast and non-dermatophyte species. Med Mycol. 2005;43(2):179-185.